• wegovy weight loss pen

Wegovy (Semaglutide) Weight Loss Injection

  • Type

    injection

  • Consumption

    subcutaneous

  • Availability

    In Stock

  • Once Weekly Injection
  • Clinically Proven
  • Licensed for Weight Loss
  • No Hidden Costs

Wegovy (Semaglutide) Weight Loss Injection

From
£0.00

Medication features

Wegovy™ is a once-weekly injectable weight loss aid which is often prescribed when other weight loss efforts have been ineffective. It is only available on prescription.

We provide confidential  follow-up and advice to all patients on their weight loss journey.

**Wegovy is not yet licensed for sale in the UK however Cloud Pharmacy will be working with the pharmaceutical provider to treat patients with the drug once it is fully approved.**

Please note: This page is only to be used as a reference of our price for this medication. If you are approved you will be offered treatment for you and the prescriber to jointly consider. However, the final decision will always be the prescriber's.
NOTE: After selecting this product, you will need to complete a short assessment, so we can make sure this medication is suitable for you.

Order by 3:30pm, Monday to Friday to be eligible for next day delivery

Free Postage

Discreet

No Hidden Costs

  • Overview

    Buy Wegovy™ Online UK

    Wegovy™ has recently been approved by the United States medicines regulator, the FDA, to aid weight loss. Like the Saxenda weight loss pen it is an injection that can be used to suppress your appetite and therefore aid in your weight loss journey. The only difference between Saxenda and Wegovy™ is that Saxenda is once daily dosing and Wegovy™ is a once weekly dosing.

    What is Wegovy™ Weight Loss Injection?

    Wegovy™ is a prescription only weight loss injection. The active ingredient in Wegovy™ is semaglutide, this is the same drug that is in Ozempic. The difference between Ozempic and Wegovy™ is that Ozempic is only licensed for use in diabetics and it comes in a different strength compared to Wegovy™, which comes in a single strength of 2.4mg.

    The Wegovy™ (semaglutide) injection 2.4 mg is an injectable prescription medicine used for adults with obesity (BMI ≥30) or overweight (excess weight) (BMI ≥27) who also have weight-related medical problems (e.g high blood pressure, type-2-diabetes, high cholesterol) to help them lose weight and keep the weight off.

    • Wegovy™ should only be used with a reduced calorie meal plan and regular exercise. Wegovy™ alone will not reduce your weight if taken alone without any other life style adjustments.
    • Wegovy™ contains semaglutide, a GLP-1 receptor agonist and should NOT be used in conjunction with other GLP-1 agonists such as Saxenda or Ozempic.
    • There is insufficient data regarding whether taking Wegovy™ in conjunction with other prescription, over-the-counter or herbal weight loss products is safe and/or effective.

    How Does Wegovy™ Work?

    Wegovy™ (semaglutide 2.4mg) is a self injectable weight loss treatment. It containts the active ingredient semaglutide which is very similar to a naturally occuring hormon in the human body called Glucagon-Like Peptide 1 (GLP-1), which belongs to a family of hormones in the body called incretins.

    After a meal GLP-1 is naturally released from your intestines to help regulate your blood sugar levels and reduce the amount of glucagon in your body. Glucagon is a naturally occurring hormone that works by inhibiting the action of insulin. As a result, it makes you feel less hungry, slows down the emptying of your stomach and makes you feel 'fuller' for longer.

    In summary, Wegovy™ 'tricks' your body into producing more GLP-1 and therefore sends signals to your brain that you are full and do not need to eat.

    Can Wegovy™ Help me Lose Weight?

    The Step 1 clinical trial for Wegovy™ conducted by Novo Nordisk saw 1,961 patiens with with obesity (BMI ≥30 kg/m2) or with overweight (BMI 27 kg/m2-29.9 kg/m2) and at least 1 weight-related comorbid condition, such as treated or untreated dyslipidemia or hypertension. Patients received Wegovy™ or placebo in addition to instruction for a reduced-calorie diet (approximately 500 kcal/day deficit) and increased physical activity counseling (recommended to a minimum of 150 min/week) throughout the trial.

    The trial resulted in a satistically significant reduction in body weight when compared to the placebo after 68 weeks. The trial showed that there was an average reduction of 14.8% in body weight in patients taking Wegovy™ vs 2.8% reduction in body weight for those taking the placebo, the patients on the placebo only reduced their calorie intake and increased physical activity.

    The results also indicated that after 68 weeks on Wegovy™, 83.5% of patients lost 5% or more of their body wieght. In the placebo group, 31.1% of patients lost 5% or more. Further clinical trials were also carried out, which showed statistically significant reductions in body weight.

    Wegovy™ Vs Saxenda

    Saxenda® (liraglutide) injection 3 mg is an injectable prescription medicine that may help some adults with excess weight (BMI ≥27) who also have weight-related medical problems or obesity (BMI ≥30) lose weight and keep the weight off. Saxenda® should be used with a reduced-calorie meal plan and increased physical activity.

    Both Wegovy™ and Saxenda® are GLP-1 receptor agonists, and are part of the same family of injectable hormone like drugs, however the main difference between the two is that Saxenda® is administered once DAILY, whereas Wegovy™ is administered once WEEKLY.

    Wegovy™ Vs Orlistat

    Orlistat 120mg capsules are an effective weight loss medication used to treat obesity and reduce overall weight gain.

    Through clinical trials, Orlistat was proven to block around one third of all fat consumed with meals. Working directly in the stomach, Orlistat can help to make weight loss more effective than with a healthy diet and increased exercise alone.

    Orlistat is prescription only, the body needs to break down dietary fats into smaller pieces before absorbing them. Orlistat works by obstructing the enzymes that break down the fats in your diet, halting the absorption process.

    The obvious difference between Wegovy™ and Orlistat is that you take Orlistat orally, where as Wegovy™ is injected. Orlistat also needs to be taken up to three times a day (after each meal) to get the best out of it meaning it is nowhere near as convenient as Wegovy™, which is injected once weekly.

    Wegovy™ and Pregnancy

    Wegovy™ may cause fetal harm. When pregnancy is recognized, discontinue Wegovy™. Discontinue Wegovy™ in patients at least 2 months before a planned pregnancy.

    Wegovy™ Summary

    How Wegovy™ WorksStimulates hormone production and suppresses appetie
    Efficacy83% of patients in clinical trial lost 5%+ of their body weight
    How to Use Wegovy™Injection, administered S.C into abdomen, thigh or upper arm once weekly
    Common Side EffectsDiarrhoea, Nausea, Vomiting, Constipation
    What is Active IngredientSemaglutide

     

  • Drug Interactions and Side Effects

    Wegovy™ Drug Interactions

    Like all medications, Wegovy™ has some drugs that will interact with it and the medication should not be used in this instance.

    • The addition of Wegovy™ in patients treated with insulin has not been evaluated. When initiating Wegovy™, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia.
    • Wegovy™ causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor the effects of oral medications concomitantly administered with Wegovy™.

    Wegovy™ Adverse Reactions

    The most common adverse reactions reported in ≥5% of patients treated with Wegovy™ arenausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distention, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, and gastroesophageal reflux disease.

  • Side Effects

    Wegovy™ Side Effects

    The most commonly reported side effects in clinical trials were:

    • Nausea (reported in 44% of patients)
    • Diarrhoea (reported in 30% of patients)
    • Vomiting (reported in 24% of patients)
    • Constipation (reported in 24% of patients) 

    Other side effects included abdominal pain, headache, fatigue, and dizziness. 

    In animal studies, semaglutide was associated with an increased risk of thyroid tumours. This link has not been determined in humans, but Wegovy should not be taken by people with a personal or family history of thyroid tumours or a condition called MEN-2.

    Wegovy has been associated with other serious side effects like acute pancreatitis, gallbladder disease, heart rate increase and kidney injury. See the Wegovy information on side effects for further details.

  • Info Leaflet

    Wegovy™ Weight Loss Injection Patient Information Leaflet

    For more information about Wegovy™, please take a look at the information leaflet below. It is important you read the Patient Information Leaflet (PIL) before using Wegovy™.

  • Warnings

    Wegovy™ Warning and Precautions

    All medications come with risks when taken, even if minimal- the following is a comprehensive list of all potential complications, warning and precautions to be taken into consideration when being prescribed Wegovy™

    • Risk of Thyroid C-Cell Tumors: Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging.
    • Acute Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide. Acute pancreatitis was observed in patients treated with Wegovy™ in clinical trials. Observe patients carefully for signs and symptoms of acute pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back, and which may or may not be accompanied by vomiting). If acute pancreatitis is suspected, discontinue Wegovy™ promptly, and if acute pancreatitis is confirmed, do not restart.
    • Acute Gallbladder Disease: In clinical trials, cholelithiasis was reported by 1.6% of Wegovy™ patients and 0.7% of placebo patients. Cholecystitis was reported by 0.6% of Wegovy™ patients and 0.2% of placebo patients. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.
    • Hypoglycemia: Wegovy™ lowers blood glucose and can cause hypoglycemia. In a trial of patients with type 2 diabetes, hypoglycemia was reported in 6.2% of Wegovy™ patients versus 2.5% of placebo patients. Patients with type 2 diabetes taking Wegovy™ with an insulin secretagogue (e.g. sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Inform patients of the risk of hypoglycemia and educate them on the signs and symptoms. Monitor blood glucose in patients with type 2 diabetes.
    • Acute Kidney Injury: There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which in some cases required hemodialysis, in patients treated with semaglutide. Patients with renal impairment may be at a greater risk of acute kidney injury, but some events have been reported in patients without known underlying renal disease. A majority of the events occurred in patients who experienced nausea, vomiting, or diarrhea, leading to volume depletion. Monitor renal function when initiating or escalating doses of Wegovy™ in patients reporting severe adverse gastrointestinal reactions and in patients with renal impairment reporting any adverse reactions that could lead to volume depletion.
    • Hypersensitivity: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with semaglutide. If hypersensitivity reactions occur, discontinue use of Wegovy™, treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist.
    • Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: In a trial of patients with type 2 diabetes, diabetic retinopathy was reported by 4.0% of Wegovy™ patients and 2.7% of placebo patients. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
    • Heart Rate Increase: Mean increases in resting heart rate of 1 to 4 beats per minute (bpm) were observed in Wegovy™ patients compared to placebo in clinical trials. More Wegovy™ patients compared with placebo had maximum changes from baseline of 10 to 19 bpm (41% versus 34%) and 20 bpm or more (26% versus 16%). Monitor heart rate at regular intervals and instruct patients to report palpitations or feelings of a racing heartbeat while at rest. If patients experience a sustained increase in resting heart rate, discontinue Wegovy™.
    • Suicidal Behavior and Ideation: Suicidal behavior and ideation have been reported in clinical trials with other weight management products. Monitor patients for depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Discontinue Wegovy™ in patients who experience suicidal thoughts or behaviors and avoid in patients with a history of suicidal attempts or active suicidal ideation.